BioVie Inc. (BIVI) 股票分析

公司概述

BioVie Inc. operates as a clinical-stage biopharmaceutical entity dedicated to developing drug therapies designed to address neurological, neurodegenerative disorders, and advanced liver disease within the United States market. The company functions within the broader Healthcare sector and specifically targets the Biotechnology industry, positioning itself as a specialized developer of innovative treatments for complex medical conditions. This biotechnology firm maintains a market capitalization of $10.86M and employs a staff of 13 individuals to advance its therapeutic pipeline. The current market capitalization of $10.86M indicates that the company is classified as a small-cap entity with a relatively modest valuation compared to large-cap pharmaceutical peers, while the absence of reported annual revenue in the available data suggests the business is still in a pre-commercialization or early development phase where capital allocation is heavily focused on research rather than sales generation.

财务健康

The company reports a net income of $-17,478,136 over the trailing twelve months, while revenue figures are not available in the current dataset, resulting in a profit margin of 0.0% that reflects the typical loss-making status of clinical-stage biotechnology firms. The EBITDA stands at $-17,968,812, a figure that aligns closely with the net income loss and highlights a cost structure where operating expenses significantly exceed any current revenue streams. Free cash flow is reported at $-8,277,755, indicating that the company is consuming cash reserves to fund its drug development activities rather than generating positive cash flow from operations. All three reported margins—gross margin, operating margin, and profit margin—are recorded at 0.0%, which signifies that the company has not yet achieved profitability or that revenue data is insufficient to calculate positive margins in the current reporting period. The balance sheet holds $20.54M in cash against $314,915 in total debt, creating a substantial liquidity buffer, yet the debt-to-equity ratio of 1.64 suggests a leveraged capital structure relative to the small equity base. Despite the high current ratio of 7.25, which indicates robust short-term liquidity and an ability to cover current liabilities multiple times over, the return on equity is -80.7% and the return on assets is -47.2%, metrics that reveal that management is currently burning capital to build an asset base rather than generating returns for shareholders.

估值评估

The company exhibits a forward P/E ratio of -0.33, while the trailing twelve-month P/E ratio is not applicable due to negative earnings, a discrepancy that implies the market is not valuing the stock based on current profitability but rather on potential future earnings trajectories once clinical trials succeed. The price-to-book ratio stands at 0.56, indicating that the market is valuing the company at a discount relative to its tangible book value, which often occurs with unprofitable biotechnology firms where asset values may not fully capture the value of the intellectual property pipeline. Although the price-to-sales ratio is not available and the EV/EBITDA is 0.52, these alternative valuation metrics further underscore that the company is being valued on an enterprise value basis that accounts for its significant cash position rather than earnings multiples. The stock has traded with a 52-week high of $13.20 and a 52-week low of $1.06, suggesting a wide trading range that reflects the high volatility inherent in small-cap biotechnology equities. With a beta of 0.56, the stock demonstrates lower price volatility relative to the broader market, moving at a slower pace than the overall index despite its status as a high-risk clinical-stage asset.

Growth & Income

Revenue growth and earnings growth year-over-year are both marked as not available, which prevents a direct comparison of growth rates but is consistent with the company's stage where revenue is negligible or zero. Since the company does not pay a dividend, indicated by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute earnings to shareholders and instead reinvests all available capital, including its $20.54M cash reserves, into research and development to advance its drug therapies for neurological and liver diseases. The overall growth and income profile is characterized by a lack of current financial growth metrics and zero income distribution, focusing entirely on capitalizing the pipeline through internal funding rather than external financing or shareholder payouts.